Polyvalent Snake Venom Vaccine Using Merged Toxoids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current snake venom vaccines, such as the CAT Vaccine, are monovalent and ineffective against venom variations within and between species and geographical populations, failing to provide broad protection against envenomation from multiple snake species, including the Southern Pacific Rattlesnake and Mojave Rattlesnake.
Innovation Solution
Development of a polyvalent vaccine using toxoids derived from venom of multiple rattlesnake species and geographical regions, as well as other venomous snakes and scorpions, to create a broadly protective vaccine that includes all dangerous components, with the option to add adjuvants and preservatives for storage and administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a monovalent vaccine is used, then the vaccine is simpler to produce and cheaper, but it provides limited protection only against a single snake species
Solution Approach 1:
The patent combines multiple monovalent vaccines into a single polyvalent vaccine formulation that includes toxoids from multiple snake species (Crotalus atrox, Crotalus oreganus, Crotalus scutulatus, and Agkistrodon piscivorus). This merging approach allows the vaccine to provide broad protection against different snake species while maintaining a single unified product structure, thereby improving adaptability without proportionally increasing complexity.
Solution Approach 2:
The polyvalent vaccine is designed to serve multiple functions by providing protection against various snake species simultaneously. The vaccine formulation includes toxoids that elicit immune responses against different venom compositions, making the single vaccine product universally applicable to multiple snakebite risks in the Western United States, thus improving versatility while maintaining practical simplicity.
2Reliability
If a monovalent vaccine is used, then the production process is simpler, but it fails to protect against venom variations within and between species
Solution Approach 1:
The patent segments the vaccine development process by separately characterizing and selecting toxoids from multiple snake species and geographical populations before combining them into a unified formulation. This segmentation allows for systematic inclusion of diverse venom components (including those from Southern Pacific Rattlesnake, Northern Pacific Rattlesnake, Mojave Rattlesnake, and Western Diamondback Rattlesnake) while maintaining a standardized manufacturing process for the final polyvalent product.
Solution Approach 2:
The vaccine employs composite material principles by combining multiple toxoid preparations from different snake species into a single polyvalent formulation. This composite approach ensures that the vaccine contains representative antigens from various venom compositions, improving reliability against venom variations while using established toxoid production methods to maintain manufacturing feasibility.
3Loss of time
If existing monovalent vaccines are used, then treatment costs are lower, but they result in prolonged treatment duration and higher costs due to ineffective protection
Solution Approach 1:
The polyvalent vaccine provides preliminary protection by eliciting broad-spectrum anti-venom antibodies before envenomation occurs. The vaccine includes toxoids from multiple species that stimulate the production of neutralizing antibodies capable of recognizing and neutralizing various snake venoms, thereby preventing the need for prolonged post-envenomation treatment and reducing overall healthcare costs despite the higher initial vaccine investment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyvalent vaccine stimulates a strong and lasting immune response, providing protection against a wide range of snake species and subspecies, significantly reducing mortality and suffering in mammals and reducing treatment duration and costs.
Implementation Method 1
toxoids derived from snakes or animals sourced from multiple geographical locations... stimulate the immune system to defend against each of the potentially dangerous components
Implementation Method 2
the neutralization process(es) disrupt enough molecular structure to render the toxoids nontoxic... produce a protective immune response
Implementation Method 3
All toxins can be denatured by physical or chemical means to produce attenuated materials known as toxoids, which immunologically resemble the source toxin
Data Source
AI summary
This disclosure relates to materials and methods useful for vaccinating mammals against the effects of envenomation by venomous organisms (including the Western Rattlesnake) by making use of venom from multiple distinct populations, subspecies or species of the organism, to make a vaccine more broadly protective against other populations, subspecies or species.